Grace Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Grace Therapeutics, Inc. (GRCE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 114.37% for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2024-08-09
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-06-30 was 114.37%.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-06-30 was 0.00%, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-09-30 was 117.96%.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-06-30 was 117.47%.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 117.94%, a 0.32% increase from fiscal 2023.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 117.56%, a 2.56% decline from fiscal 2022.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 120.65%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2024-06-30 | 114.37% 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | 117.94% 10-K · filed 2024-06-21 | |||
| 2023-12-31 | 117.80% 10-Q · filed 2024-02-12 | |||
| 2023-09-30 | 118.40% 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | 117.56% 10-K · filed 2024-06-21 | |||
| 2022-12-31 | 117.56% 10-Q · filed 2024-02-12 | |||
| 2022-09-30 | 117.96% 10-Q · filed 2022-11-14 | 117.56% 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | 117.47% 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 120.65% 10-K · filed 2023-06-23 | |||
| 2021-12-31 | 120.66% 10-Q · filed 2022-02-14 | 120.66% 10-Q · filed 2022-02-14 | ||
| 2020-12-31 | 0.00% 10-Q · filed 2022-02-14 | 0.00% 10-Q · filed 2022-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |